Skip to main content

Table 2 Baseline eGFR and eGFR stages classification

From: The potential of cystatin C as a predictive biomarker in pulmonary hypertension

Variables

Total (N = 398)

CW (n = 72)

No-CW (n = 326)

P-value

CKD stages, n (%)a

   

0.010

 Stage 1

159 (39.9)

17 (23.6)

142 (43.6)

 

 Stage 2

186 (46.7)

41 (56.9)

145 (44.5)

 

 Stage 3

51 (12.8)

14 (19.4)

37 (11.3)

 

 Stage 4

2 (0.5)

0 (0.0)

2 (0.6)

 

eGFR, mL/min/1.73m2

 2009 CKD-EPIcr

80.64 ± 21.93

76.00 ± 22.14

81.67 ± 21.79

0.047

 2012 CKD-EPIcys

81.94 ± 26.34

73.35 ± 26.74

83.75 ± 25.89

0.002

 2012 CKD-EPIcr-cys

81.10 ± 22.82

74.21 ± 23.24

82.62 ± 22.47

0.005

 2021 CKD-EPIcr

84.61 ± 22.06

80.19 ± 22.45

85.59 ± 21.89

0.060

 2021 CKD-EPIcr-cys

84.15 ± 23.10

77.12 ± 23.69

85.71 ± 22.71

0.004

 MDRD

78.57 ± 22.16

74.72 ± 22.06

79.42 ± 22.13

0.103

 Cockcroft-Gault

78.96 ± 36.34

75.31 ± 38.18

79.77 ± 35.95

0.347

  1. CKD Chronic kidney disease, CKD-EPI CKD-Epidemiology Collaboration, Cr Creatinine, CW Clinical worsening, Cys Cystatin C, eGFR Estimated glomerular filtration rate measured in ml/min per 1.73 m2, MDRD Modification of Diet in Renal Disease
  2. aeGFR stages were determined according to Kidney Disease Improving Global Outcomes guidelines. Baseline GFR was estimated using different equations